- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05645146
Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sarah Jones
- Phone Number: 813-745-7525
- Email: Sarah.Jones@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Principal Investigator:
- Jennifer Vidrine, PhD, MS
-
Sub-Investigator:
- Damon Vidrine, DrPH, MS
-
Sub-Investigator:
- Steven Sutton, PhD
-
Sub-Investigator:
- Vani Simmons, PhD
-
Contact:
- Sarah Jones
- Phone Number: 813-745-7525
- Email: Sarah.Jones@moffitt.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 100 cigarettes or more smoked in participants lifetime
- Speaks English
- Currently smoke 1 cigarette or more in the past 30 days
- History of cervical cancer or high grade cervical dysplasia
- Has a working smartphone
- Has a valid home address
- Reside in Florida at the time of study enrollment
Exclusion Criteria:
- Receiving behavioral or pharmacological tobacco treatment
- Household member enrolled in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1: Standard Treatment
Participants will receive a connection to the Tobacco Free Florida Quitline and a 12 week supply of nicotine replacement therapy (the patch and lozenges)
|
Phone counseling with the state tobacco quitline
Participants will be provided with a 12 week supply of nicotine patches
Participants will be provided with a 12 week supply of nicotine lozenges
|
Experimental: Group 2: Motivation and Problem Solving (MAPS) counseling
Participants will receive a 12 week supply of nicotine replacement therapy (the patch and lozenges) along with the MAPS intervention, which consists of 6 MAPS counseling calls over 12 months, and individually tailored SMS text content driven by monthly smartphone delivered check-ins for 24 months
|
Participants will be provided with a 12 week supply of nicotine patches
Participants will be provided with a 12 week supply of nicotine lozenges
MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation.
Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MAPS vs Standard Treatment in facilitating long term smoking abstinence
Time Frame: at 24 months
|
The primary outcome of this study is self-reported, 7 day point prevalence abstinence over time through the 24 month assessment where participants who report no smoking in the previous 7 days at follow-up assessment are considered abstinent. Efficacy of MAPS vs Standard Treatment will be measured by comparing the number of participants in each group who were able to quit smoking and maintain smoking abstinence for 2 years. |
at 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jennifer Vidrine, PhD, MS, Moffitt Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Precancerous Conditions
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Uterine Cervical Dysplasia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- MCC-21885
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Smoking Cessation treatment delivered by Tobacco Free Florida Quitline
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; National Center for Advancing Translational Sciences...TerminatedSmoking CessationUnited States
-
Consumer Wellness SolutionsNorthwestern University; SRI InternationalCompletedObesity | Overweight | Cigarette SmokingUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); Roswell Park Cancer InstituteCompletedSmoking CessationUnited States
-
University of LouisvilleCompleted
-
Massachusetts General HospitalRobert Wood Johnson FoundationCompletedSmoking Cessation | PregnancyUnited States
-
University of Alabama at BirminghamNational Institute on Drug Abuse (NIDA)CompletedCigarette Smoking | Home Access to Internet and Email | Cognitively and Physically Able to Participate | English Speaking and ReadingUnited States
-
University of Alabama at BirminghamUniversidade Estadual de LondrinaRecruiting
-
M.D. Anderson Cancer CenterNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)CompletedCurrent Smoker | Cigarette SmokingUnited States
-
M.D. Anderson Cancer CenterCancer Therapy and Research Center, TexasActive, not recruiting
-
University of VirginiaNational Institutes of Health (NIH)CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Smoking, Hookah | Smoking, Cigar | Smoking, PipeUnited States